THYNODE: In Vivo Multispectral Optoacoustic Imaging of Thyroid Nodules

Sponsor
University Medical Center Groningen (Other)
Overall Status
Recruiting
CT.gov ID
NCT04730726
Collaborator
(none)
50
1
1
19
2.6

Study Details

Study Description

Brief Summary

Thyroid nodules are common in clinical practice. Head and neck ultrasound is recommended as a routine examination for all patients with thyroid lesions. The Thyroid Imaging Reporting And Documentation System (TIRADS) criteria helps to estimate the risk of malignancy based on ultrasound patterns and nodule sizes guiding the performance of fine-needle-aspiration (FNA). Approximately 20% of FNA results cannot be specified whether being benign or malig-nant tissue. A definitive diagnosis can only be made from histopathology after diagnostic (hemi)thyroidectomy. However, (hemi)thyroidectomy has disadvantages as it leads to over-treatment and has a risk of postoperative morbidity (e.g. hypothyroidism and laryngeal nerve injury). Furthermore, (hemi)thyroidectomy is known to be associated with poor quality of life. Clearly, there is an unmet need for additional diagnostic tools in order to identify malignant thyroid nodules and thereby support the decision making for treatment of the thyroid.

Multispectral optoacoustic tomography (MSOT) is an innovative, non-invasive imaging method currently available in the UMCG that enables visualization of endogenous chromophores and exogenous contrast agents using the generation of ultrasound waves due to light absorption by using high frequency pulsed laser light. Recently, this system has been used by other groups for non-invasive determination of thyroid nodules. Results show that multispectral optoacoustic imaging of thyroid nodules may distinguish benign from malignant nodules. However, most certainly, a larger cohort is necessary to confirm this finding.

Condition or Disease Intervention/Treatment Phase
  • Device: MSOT Acuity Echo
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
50 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Diagnostic
Official Title:
In Vivo Multispectral Optoacoustic Imaging of Thyroid Nodules
Actual Study Start Date :
Sep 1, 2020
Anticipated Primary Completion Date :
Dec 1, 2021
Anticipated Study Completion Date :
Apr 1, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: Patients with thyroid nodules

Patients with thyroid nodules that underwent or will undergo an ultrasound with FNA if indicated and if indicated will be scheduled for a (hemi)thyroidectomy

Device: MSOT Acuity Echo
Hybrid optoacoustic and ultrasonography imaging

Outcome Measures

Primary Outcome Measures

  1. MSOT signals of endogenous biomarkers [2 years]

    HbO2, HbR, HbT, sO2, fat, water and collagen

Secondary Outcome Measures

  1. Potential correlation FNA [2 years]

    To explore a potential correlation between endogenous optoacoustic signals in vivo with cytology (the standard-of-care of Bethesda scoring system derived from FNA)

  2. Potential correlation ultrasound [2 years]

    To explore a potential correlation between endogenous optoacoustic signals in vivo with TIRADS ultrasonography scoring system (the scoring system used by radiologists when evaluating the thyroid nodules with ultrasonography).

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Patients with thyroid nodules who underwent or will undergo an ultrasonography (with TIRADS score) with FNA if indicated and will be scheduled for a (hemi)thyroidectomy if indicated;

  2. Age ≥ 18 years;

  3. Written informed consent.

Exclusion Criteria:
  1. Medical or psychiatric conditions that compromise the patients' ability to give informed consent;

  2. Previous surgery in head and neck area

  3. Previous radiotherapy in head and neck area

  4. Pregnancy

Contacts and Locations

Locations

Site City State Country Postal Code
1 University Medical Center Groningen Groningen Netherlands 9713GZ

Sponsors and Collaborators

  • University Medical Center Groningen

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Schelto Kruijff, MD PhD, Dr., University Medical Center Groningen
ClinicalTrials.gov Identifier:
NCT04730726
Other Study ID Numbers:
  • 201900301
First Posted:
Jan 29, 2021
Last Update Posted:
Jan 29, 2021
Last Verified:
Jan 1, 2021
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 29, 2021